 |
Welcome
TVM
Clinical Evidence
How to Buy / Clinical Training
US Reimbursement
Investor Relations
Contact Us
|
|
Next generation CardioQ–ODM™ monitor released for sale 23 April 2008 Deltex Medical Group plc ("Deltex Medical"), the UK's leading haemodynamic monitoring company, today announces the release of the CardioQ–ODM™, the next generation of its market leading oesophageal Doppler monitor (ODM).
The CardioQ–ODM™ is being made available for sale initially in the UK and in the Company's key markets in Continental Europe, Latin America and the Far East. The Company is preparing its application for clearance of the CardioQ–ODM™ by the US regulatory authorities and expects to release it into the US market in the latter part of 2008. To support its continuing expansion in the USA in the meantime, the Company intends to use its remaining stocks of CardioQ™ monitors, supplemented as required by CardioQ™ units recovered from existing customers under CardioQ–ODM™ upgrade schemes. Deltex Medical's Chief Executive, Andy Hill commented: "The launch of the CardioQ–ODM™ monitor further extends our first-mover advantage in the fast-growing market for technology that allows real-time management of patients' circulating blood volumes before, during and after surgery and in critical care. "Our decision to call the new monitor the CardioQ–ODM™ reflects the perception in global medical markets that Deltex Medical is THE oesophageal Doppler monitoring company. This is timely, as it is becoming increasingly clear that oesophageal Doppler guided fluid management allows doctors to intervene earlier, more safely and more effectively than any fluid management protocols that use other technologies which do not directly measure blood flow." For further information, please contact: Deltex Medical Group plc 01243 774 837 Gavin Anderson & Company 020 7554 1400 Charles Stanley Securities 020 7149 6000
Deltex Medical manufactures and markets the CardioQ™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body Ð 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ™, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier. The CardioQ™ incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ™ provides clinicians with the ability to optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been proven to improve the speed and quality of patient recovery and reduce hospital stay. There are already around 1,500 CardioQ™s currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 90 clinical publications on the use of the CardioQ™ which have repeatedly:
The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ™ in a similar format and is used for taking snapshots or monitoring over short periods.
|